Navigation Links
Scientists discover new way protein degradation is regulated
Date:4/26/2013

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins. Researchers at Rockefeller University and the Howard Hughes Medical Institute have identified a new way that the cell's protein recycler, the proteasome, takes care of unwanted and potentially toxic proteins, a finding that has implications for treating muscle wasting, neurodegeneration and cancer.

The consensus among scientists has been that the proteasome is constantly active, chewing up proteins that have exceeded their shelf life. A mounting body of evidence now suggests that the proteasome is dynamically regulated, ramping up its activity when the cell is challenged with especially heavy protein turnover. The researchers, postdoctoral associate Park F. Cho-Park and Hermann Steller, head of the Strang Laboratory of Apoptosis and Cancer Biology at Rockefeller, have shown that an enzyme called tankyrase regulates the proteasome's activity. In addition, Cho-Park and Steller demonstrate that a small molecule called XAV939, originally identified by scientists at Novartis who developed it as therapeutic for colon cancer, inhibits tankyrase and blocks the proteasome's activity. The research is reported in today's issue of the journal Cell.

"Our findings have tremendous implications for the clinic since it gives a new meaning to an existing class of small-molecule compound," says Steller, Strang Professor at Rockefeller and an investigator at HHMI. "In particular, our work suggests that tankyrase inhibitors may be clinically useful for treating multiple myeloma."

Tankyrase was originally identified in the late 1990s by Rockefeller's Titia de Lange and her colleagues in the Laboratory for Cell Biology and Genetics, who showed that it plays a role in elongating telomeres, structures that cap and protect the ends of chromosomes. In a series of experiments in fly and human cells, Cho-Park and Steller discovered that tankyrase uses a process called ADP-ribosylation to modify PI31, a key factor that regulates the activity and assembly of proteasome subunits into the active complex called 26S. By promoting the assembly of more 26S particles, cells under stress can boost their ability to break down and dispose of unwanted proteins.

The proteasome is currently a target for developing cancer therapeutics. The FDA has approved Velcade, a proteasome inhibitor, for the treatment of multiple myeloma and mantle cell lymphoma. However, patients on Velcade can experience peripheral neuropathy or become resistant to the drug.

Multiple myeloma cells need increased proteasome activity to survive. Preliminary data from Cho-Park and Steller show that XAV939 can block the growth of multiple myeloma cells by inhibiting the assembly of additional proteasomes without affecting the basal level of proteasomes in the cell. This selective targeting may mean fewer side effects for patients. "Drugs, such as XAV939, that inhibit the proteasome through other mechanisms than Velcade may have significant clinical value," says Steller.

The findings by Cho-Park and Steller also link, for the first time, metabolism and regulation of the proteasome. Sometimes the proteasome digests too much protein, which can lead to loss of muscle, says Steller.

"This discovery reveals fundamental insights into protein degradation, a process important for normal cell biology, and a key factor in disorders such as muscle wasting and neurodegeneration," said Stefan Maas of the National Institutes of Health's National Institute of General Medical Sciences, which partly supported the study. "Intriguingly, the findings also enlighten ongoing research on cancer therapies, exemplifying the impact of basic research on drug development."


'/>"/>

Contact: Joseph Bonner
joseph.bonner@rockefeller.edu
212-327-8998
Rockefeller University
Source:Eurekalert

Related biology news :

1. Europe needs genetically engineered crops, scientists say
2. Scientists awarded $5.5 million for wheat, rice blast research
3. Study led by NUS scientists reveals escalating cost of forest conservation
4. Scientists map all possible drug-like chemical compounds
5. Scientists find ethnicity linked to antibodies
6. University of Southern California scientists reveal natural process that blocks viruses
7. Scientists look to ancient past to better predict how species may respond climate change
8. Scientists learn what makes nerve cells so strong
9. Inter-American Network of Science Academies celebrates women scientists -- April 17 event
10. A novel surface marker helps scientists fish out mammary gland stem cells
11. Scientists stress need for national marine biodiversity observation network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... NC (PRWEB) , ... August 15, 2017 , ... ... 2017, celebrating 10 years of successes helping medical technology companies and inventors develop and ... to a renowned full-service national engineering firm with a portfolio of clients in the ...
(Date:8/15/2017)... ... 15, 2017 , ... The Conference Forum and The Trout ... a series of upcoming panels and events. The partnership culminates with the 4th ... in New York City. , “With our experience in producing the Immuno-Oncology 360° NYC ...
(Date:8/14/2017)... ... 14, 2017 , ... The Conference Forum has confirmed the one-day ... on September 6, 2017 at the Marriott Copley Place in Boston, MA. , Returning ... and Regulatory Strategy, Pfizer Innovative Research Lab, Pfizer, who leads 19 industry speakers in ...
(Date:8/10/2017)... , ... August 09, 2017 , ... ... help the agriculture industry reach its ideal customers with the right message. Their ... , “As a Midwest company, we realize how crucial the agriculture industry is,” ...
Breaking Biology Technology: